Proven HA vs. Emerging Hydrogel Technology
Monovisc and Arthrosamid are both single-injection treatments for knee osteoarthritis, but they work in fundamentally different ways. Monovisc restores joint lubrication with cross-linked hyaluronic acid that lasts 6-12 months. Arthrosamid integrates a permanent hydrogel into the joint lining that may provide relief for 2 or more years. This comparison helps you understand what each offers and their significant tradeoffs.
Side-by-Side Comparison
| Factor | Arthrosamid | Monovisc |
|---|---|---|
| Type | Polyacrylamide hydrogel | Cross-linked hyaluronic acid |
| Injections | 1 (single) | 1 (single) |
| Source | Synthetic | Avian (rooster comb) |
| Mechanism | Integrates into joint lining | Lubricates joint surfaces |
| Duration | 2+ years | 6-12 months |
| FDA approved (US) | No (as of 2025) | Yes |
| Self-pay cost | $2,500-$5,000 | $700-$1,100 |
| Medicare | Not covered | Yes |
| Bird allergy safe | Yes (synthetic) | No (avian) |
Monovisc: The Established Standard
Monovisc is a well-known cross-linked HA product that delivers 4 mL of viscous gel directly into the knee joint. It has been FDA-approved since 2014 and is covered by Medicare and most private insurers. For many patients, it is the default single-injection HA choice.
Advantages
Considerations
Arthrosamid: The Long-Duration Alternative
Arthrosamid works differently from all HA products. Its polyacrylamide hydrogel (97.5% water, 2.5% polyacrylamide) integrates into the inner wall of the joint capsule. Rather than simply lubricating the joint, it becomes part of the synovial lining, potentially restoring the joint’s natural ability to manage itself.
Advantages
Considerations
Different Solutions for Different Patients
These two products serve different patient profiles:
Monovisc patients typically want a straightforward, covered treatment they can repeat as needed. The annual rhythm of getting an injection every 6-12 months becomes routine. Insurance handles most of the cost, and the product’s track record provides peace of mind.
Arthrosamid patients are typically frustrated with repeat injections or looking for a longer-lasting solution. They may have tried HA products with diminishing returns and want something fundamentally different. They are willing to pay more upfront for the possibility of multi-year relief.
Making Your Decision
Choose Monovisc if:
- You want FDA-approved, insured treatment
- You prefer a proven product with established data
- Budget matters and you want insurance to cover the cost
- You are comfortable with repeating treatment every 6-12 months
Consider Arthrosamid if:
- You are tired of repeating HA injections
- You can pay $2,500-$5,000 out of pocket
- You want the possibility of multi-year relief
- You accept using a product not yet FDA-approved in the US
- You have access to a qualified provider
Frequently Asked Questions
Can I try Monovisc first and Arthrosamid later?
Yes. Starting with the insured, established option makes sense for most patients. If Monovisc works well but you tire of repeating it, Arthrosamid may be worth exploring.
Does Arthrosamid affect future knee replacement?
Current evidence suggests Arthrosamid does not interfere with knee replacement surgery. The hydrogel is not believed to complicate surgical techniques or implant placement. However, long-term surgical data is still limited.
Why is Arthrosamid so much more expensive?
Three factors: it is not insured, it is not yet competing in the FDA-approved market, and its longer duration justifies premium pricing. If FDA approval comes, insurance coverage could dramatically lower the patient cost.
Is Monovisc safe for everyone?
Monovisc is avian-derived, so patients with bird or egg allergies should avoid it. For those patients, non-avian HA options like Durolane or Euflexxa are appropriate. Arthrosamid is also allergy-safe since it is synthetic.
How do I find a provider who offers Arthrosamid?
In the US, availability is limited. Some providers may offer it through clinical trial participation or special access programs. The product is more widely available in the UK, Australia, and parts of Europe.
The Bottom Line
Monovisc is today’s practical choice: proven, insured, widely available, and effective for 6-12 months per injection.
Arthrosamid is tomorrow’s promise: longer-lasting, fundamentally different technology, but not yet FDA-approved and expensive out of pocket.
For most US patients, Monovisc remains the recommended starting point. Keep an eye on Arthrosamid as data grows and regulatory status evolves.
Find Knee Injection Specialists
Connect with providers offering the latest knee OA treatments.
Your information is secure. See our Privacy Policy and Terms of Service.
Thank You!
We've received your request. A provider specialist will contact you within 1-2 business days to help you find the right care.
What happens next?
- 1 We'll verify your insurance coverage
- 2 Match you with quality providers in your area
- 3 Contact you to discuss your options
Questions? Browse our guides:
How to Choose a ProviderEmerging Treatment Updates
Stay informed about new knee osteoarthritis treatments and research.
Join 10,000+ readers. No spam.